2. Academic Validation
  3. Asthma phenotypes and T-bet protein expression in cells treated with Fluticasone Furoate/Vilanterol

Asthma phenotypes and T-bet protein expression in cells treated with Fluticasone Furoate/Vilanterol

  • Pulm Pharmacol Ther. 2020 Feb;60:101886. doi: 10.1016/j.pupt.2020.101886.
Zahra Alizadeh 1,  Esmaeil Mortaz 2,  Marzieh Mazinani 1,  Mohammad Reza Fazlollahi 1,  Hassan Heidarnezhad 3,  Ian Adcock 4,  Mostafa Moin 5
Affiliations

Affiliations

  • 1 Immunology, Asthma and Allergy Research Institute, Tehran University of Medical Sciences, No. 62, Dr. Gharib St, p.o.box: 14185-863, Tehran, Iran.
  • 2 Clinical Tuberculosis and Epidemiology Research Center, National Research Institute of Tuberculosis and Lung Diseases (nritld), Shahid Beheshti University of Medical Sciences, p.o.box: 198396-3113, Tehran, Iran; Department of Immunology, Faculty of Medicine, Shahid Beheshti University of Medical Sciences, p.o.box: 198396-311, Tehran, Iran.
  • 3 Clinical Tuberculosis and Epidemiology Research Center, National Research Institute of Tuberculosis and Lung Diseases (nritld), Shahid Beheshti University of Medical Sciences, p.o.box: 198396-3113, Tehran, Iran.
  • 4 Airway Disease Section, National Heart and Lung Institute, Imperial College London, South Kensington Campus, London, SW7 2AZ, UK.
  • 5 Immunology, Asthma and Allergy Research Institute, Tehran University of Medical Sciences, No. 62, Dr. Gharib St, p.o.box: 14185-863, Tehran, Iran; Children's Medical Center, Tehran University of Medical Sciences, No. 62, Dr. Gharib St, P.O.Box: 14185-863, Tehran, Iran. Electronic address: mmoin@sina.tums.ac.ir.
PMID: 31917328 DOI: 10.1016/j.pupt.2020.101886
Abstract

Asthma is a complex disease with diverse clinical manifestations ranging from mild to severe. Despite existing guidelines for asthma recognition and treatment, still a proportion of patients stay uncontrolled. Combinational therapy which comprises inhaled corticosteroids (ICS) and a long acting B2 adrenreceptor agonist (LABA) has been suggested to control asthma. In this study T-bet expression was attested in CD4 T cells treated with Fluticasone Furoate (FF), Vilanterol (V) and FF/V combination in severe asthmatic patients compared to patients with moderate asthma and healthy controls using Immunocytochemistry (ICC). First, CD4 T cells were isolated from PBMCs of 12 patients and controls using CD4 T Cell Isolation kit. Subsequently, isolated CD4 T cells were cultured with FF, V and FF/V for 1 h. To accomplish ICC, cells were incubated with anti-T-bet antibody, and then stained with HRP-bound secondary antibody. T-bet expression was evaluated using light microscopy. Statistical analyses were performed using R 3.5.2 software and visualized by ggplot2 3.1.0 package. Significant increasing in T-bet expression was seen in CD4 T cells from patients with moderate asthma treated with FF and FF/V. Suggesting conclusion would be distinct mechanisms responsible for severe asthma and moderate asthma in the patients and the needs for novel therapies. Further molecular studies in different asthma phenotypes would be instructive for asthma treatment.

Keywords

Corticosteroid; Long-acting b2 agonist; Moderate asthma; Severe asthma; T-box transcription factor.

Figures
Products